Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wibmer, C; Amrein, K; Fahrleitner-Pammer, A; Gilg, MM; Berghold, A; Hutterer, GC; Maurer-Ertl, W; Gerger, A; Leithner, A; Pichler, M; Szkandera, J.
Serum sclerostin levels in renal cell carcinoma patients with bone metastases.
Sci Rep. 2016; 6(4):33551-33551 Doi: 10.1038/srep33551 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Wibmer Christine Linda
Co-Autor*innen der Med Uni Graz
Amrein Karin
Berghold Andrea
Fahrleitner-Pammer Astrid
Gerger Armin
Gilg Magdalena Maria
Hutterer Georg
Leithner Andreas
Maurer-Ertl Werner
Pichler Martin
Szkandera Joanna

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker for the use of sclerostin-directed antibodies. As renal cell carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum sclerostin levels in RCC patients. Our study included 53 RCC patients (19 with bone metastases, 25 with visceral metastases and 9 with localized disease) and 53 age- and gender-matched non-osteoporotic controls. Frozen serum samples were subjected to sclerostin quantitative sandwich ELISA. The mean serum sclerostin levels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86). Analysis of variance showed no difference between the subgroups of RCC patients with regard to visceral or bone metastases or localized disease (p = 0.22). There was no significant association between eGFR (estimated glomerular filtration rate) and serum sclerostin levels in RCC patients (r = 0.05; p = 0.74) and controls (r = 0.06; p = 0.68). Our results indicate that serum sclerostin levels appear not to be a valuable biomarker to assess the occurrence of bone metastases in RCC patients.

© Med Uni Graz Impressum